EMA recommends approval of Eylea (aflibercept) for treatment of visual impairment due to diabetic macular edema

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has recommended for approval the use of Eylea (aflibercept) for treatment of visual impairment due to diabetic macular edema (DME). According to the US company, Regeneron (NASDAQ:REGN), the drug’s sponsor, the decision of the European Commission is expected in the second half of 2014. Commenting on the CHMP decision, George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories stated, “Diabetes is a growing health concern worldwide and this milestone brings us one step closer to being able to offer patients and physicians in the European Union a new therapeutic option for the treatment of diabetic macular edema”.